論文・技術情報追加のお知らせ

1. Comparative Analysis of Adverse Events Linked to PEG-rhG-CSF and rhG-CSF in Real-World Settings: Disproportionate Examination of the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database.

PEG製剤で副作用頻度・発現早期化

対象DB：FAERS

2. Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS).

心筋梗塞等の新規リスクを確認

対象DB：FAERS

3. Calcium supplementation and the risk of type 2 diabetes.

カルシウム摂取が2型糖尿病リスク増

対象DB：FAERS

4. Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database.

小児の抗てんかん薬で精神症状多発

対象DB：FAERS

5. Retrospective analysis of pembrolizumab-related adverse reactions and death outcomes based on the FAERS database.

ペムブロリズマブは高齢者で致死率高

対象DB：FAERS

6. Evaluation of post-market adverse events of lubiprostone: a real-world adverse event analysis from the FAERS database.

ルビプロストンは重篤な消化器副作用に注意が必要

対象DB：FAERS

7. Signal detection of ferric carboxymaltose-induced serious adverse events: disproportionality analysis of FAERS and VigiBase data and systematic review of case reports.

フェリックカルボキスマルトースは重篤副作用に注意が必要

対象DB：FAERS,VigiBase

8. Drug-Associated Tendinopathies and Ligament Disorders: Results from a Retrospective Pharmacovigilance Study Using Disproportionality Analysis.

腱・靭帯障害、既知薬剤に加え新規関連薬も報告

対象DB：FAERS,VAERS

9. Assessing the association between drug use and ischaemic colitis: a retrospective pharmacovigilance study using FDA Adverse Event data.

薬剤誘発虚血性大腸炎、警告不足多し

対象DB：FAERS

10. Safety Profile of Istradefylline in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials and Disproportionality Analysis Using FAERS.

イストラデフィリンは副作用リスク増加を示す

対象DB：FAERS

11. Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system.

アムロジピンは浮腫やショックなど多様な副作用リスクを示す

対象DB：FAERS

12. Exploring the Risk of Adverse Drug Events in Combination with antiparkinsonics and antipsychotics - a two-decade real-world pharmacovigilance analysis based on the FAERS database.

抗パーキンソン薬と抗精神薬の併用で幻覚や感染リスク増加

対象DB：FAERS

13. Adverse events affecting recovery from seasonal influenza vaccination in the hypertensive population: A population-based pharmacovigilance analysis.

高血圧者のインフル注射部位反応多発

対象DB：FAERS,VAERS

14. Peripheral neuropathy associated with immunomodulatory drugs: a pharmacovigilance analysis based on the FDA adverse event reporting system database.

IMiDs使用で末梢神経障害のリスクに差異あり

対象DB：FAERS

15. Association of Vancomycin Plus Piperacillin-Tazobactam With Acute Kidney Injury: Differentiating Pseudo-Injury From True Nephrotoxicity.

VPTは偽腎障害示唆、真腎障害否定

対象DB：FAERS

16. Exploring the Top 50 Drugs Associated with Restless Legs Syndrome Based on the FDA Data from 2004 to 2024.

薬剤性むずむず脚症候群は若年女性に多く、早期発症が特徴

対象DB：FAERS

17. Pharmacovigilance Study on Adverse Events of Nicotine Replacement Therapy, Bupropion, and Varenicline in Patients with Chronic Obstructive Pulmonary Disease.

COPD禁煙薬は精神・神経・消化系副作用に注意が必要

対象DB：FAERS

18. A disproportionality analysis of adverse events associated with ertapenem using the FAERS database from 2004 to 2024.

エルタペネムは神経精神障害リスクが高く、65歳以上で注意必要

対象DB：FAERS

19. Safety of the contrast enhancement agent sulfur hexafluoride in ultrasound: Analysis of the Federal Drug Administration Adverse Event Reporting System database.

硫化六フッ素の超音波造影剤はアナフィラキシー多発し、重篤例も報告

対象DB：FAERS

20. Musculoskeletal adverse events reported post-hepatitis B vaccination in the vaccine adverse event reporting system.

B型肝炎ワクチンは筋骨格系副反応と関連、注意必要

対象DB：FAERS,VAERS

21. Hypoglycemia associated with fluoroquinolone: a pharmacovigilance analysis from 2014 to 2023 based on the FDA adverse event reporting system.

フルオロキノロン系薬剤による低血糖は早期発症で重篤化リスクあり

対象DB：FAERS

22. Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system.

ボルチオキセチンの副作用に新規リスクを多数確認

対象DB：FAERS

23. An in-depth exploration of the association between olanzapine, quetiapine and acute pancreatitis based on real-world datasets and network toxicology analysis.

オランザピン・クエチアピンが急性膵炎リスク

対象DB：FAERS

24. FDA Adverse Event Reporting System (FAERS) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERS.

FAERSは安全監視に有用だが、正確な解析と解釈が重要

対象DB：FAERS

25. Disproportionality analysis of progestogens and estrogens demonstrates increased meningioma risk.

ホルモン剤ごとに髄膜腫リスク差が大きく、個別評価が重要

対象DB：FAERS

26. Safety comparisons among different subcutaneous anticoagulants for venous thromboembolism using FDA adverse event reporting system.

高齢者における3抗凝固薬の副作用リスク差を示唆

対象DB：FAERS

27. Medication errors in malaria management in children: insights from pharmacovigilance data in the Democratic Republic of Congo.

コンゴで小児マラリア治療の薬物誤用が多数発生

対象DB：VigiBase

28. Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries.

セマグルチドは眼合併症リスク増加を示唆

対象DB：VigiBase

29. Association Between Ceftriaxone Use and Biliary Infections in Patients With Pneumonia: A Nationwide Retrospective Cohort Study.

セフトリアキソン使用で胆道感染リスクがわずかに増加

対象DB：DPC

30. Obesity and risk of post-operative pneumonia among older adult patients with hip fracture: an obesity paradox.

低BMIで術後肺炎リスク増、高BMIはリスク低減（肥満パラドックス）

対象DB：DPC

31. Elevated amputation rates in COVID-19 survivors: Insights from a large-scale Japanese cohort study.

COVID-19後、切断リスクが2年以上持続し増加

対象DB：NDB

32. Current Trends in Computed Tomography Practices in Japan and the Role of Referring Physicians in Radiation Exposure Management.

日本のCT検査数は増加し過剰利用懸念

対象DB：NDB

33. Patient characteristics and pharmacologic treatment patterns in antifibrotic-treated patients with fibrosing interstitial lung diseases: real-world results from a claims database.

IPFでは抗線維化薬単剤が多く、PPFやSSc-ILDでは併用療法が一般的

対象DB：MDV

34. Treatment of Long Coronavirus Disease in Japan: A Nationwide Study of Symptom-Associated Drug Prescriptions.

日本のLong COVIDは多様な症状で薬剤使用も多様

対象DB：MDV

35. Have social prescribing referrals reduced appointment pressures on primary care? Evidence from Electronic Healthcare Records.

社会的処方でGP受診が有意に減少

対象DB：CPRD

36. Long-term outcomes following alternative second-line oral glucose-lowering treatments: Results from the real-world progression in type 2 diabetes mellitus United Kingdom (RAPIDS-UK) model.

SGLT2阻害薬は他剤より合併症リスク低減

対象DB：CPRD

37. Trends in prevalence of anaemia among people living with HIV in the UK: 20 cross-sectional analyses using population-based electronic primary healthcare records.

HIV患者の貧血は20年間で増加傾向

対象DB：CPRD

38. Loop diuretics, heart failure diagnosis and outcome in primary care.

ループ利尿薬処方後、HF評価は少数で死亡率に差

対象DB：CPRD

39. Can large language models detect drug-drug interactions leading to adverse drug reactions?

ChatGPTとClaudeはDDI検出に優れる

対象DB：FPVD

40. Comparative effectiveness of romosozumab versus teriparatide for fracture prevention: A new-user, active comparator design.

ロモソズマブは骨折予防でテリパラチドより有効

対象DB：DeSC

41. Observational Study of Corticosteroid Phobia Using the TOPICOP Score among Adults and Caregivers of Children with Atopic Dermatitis in Japan.

BVに関連する予期せぬ有害事象を検出

対象DB：DeSC